Rnai Technology Market, By Application (Drug Discovery and Development, Therapeutics, Functional Genomics, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CMOs, Others), By Geography (North America, L

Rnai Technology Market, By Application (Drug Discovery and Development, Therapeutics, Functional Genomics, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CMOs, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global RNAi technology market growth is driven by growing applications of RNA interference technology in therapeutics development and research. RNA interference or RNAi refers to the process of gene silencing mediated by short interfering RNAs (siRNAs) or microRNAs (miRNAs). It has emerged as a powerful tool for selective inhibition of gene expression and functional genomics screens. RNAi holds immense potential for developing novel therapeutics by silencing specific disease-causing genes. The development of safe and effective delivery systems further contributes to the commercialization of RNAi-based therapies. Significant investments in RNAi research and development from biopharma companies and government organizations are resulting in a strong product pipeline.

Market Dynamics:

Global RNAi technology market growth is driven by increasing applications of RNAi technology for developing treatments across therapeutic areas. Several drug candidates targeting metabolic, cardiovascular and neurodegenerative disorders are currently under clinical trials. The strong product pipeline and entry of novel RNAi drugs are creating high optimism around the therapeutic potential of this technology. However, technical challenges in RNAi delivery and off-target effects can hamper the market growth. Moreover, requirement of high capital investments for building R&D infrastructure and clinical development deters many small companies. Ongoing research on overcoming the delivery challenges through novel delivery systems such as lipid nanoparticles, polymeric nanoparticles and ligand-conjugated molecules can offer market growth opportunities. Promising clinical outcomes of RNAi-based drugs in late-stage trials can offer market growth opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global RNAi technology market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global RNAi technology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Mirna Therapeutics, and Quark Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market

Detailed Segmentation-

• By Application
• Drug Discovery and Development
• Therapeutics
• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Others
• Functional Genomics
• Other
• By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CMOs
• Others
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Alnylam Pharmaceuticals
• OriGene Technologies, Inc.
• Arrowhead Pharmaceuticals
• Dicerna Pharmaceuticals
• Silence Therapeutics
• Ionis Pharmaceuticals
• Merck & Co.
• Qiagen N.V.
• Thermo Fisher Scientific
• Synlogic
• Benitec Biopharma
• Gradalis
• Sirnaomics, Inc.
• Marina Biotech
• Quark Pharmaceuticals
• Regulus Therapeutics
• GeneCare Research Institute Co., Ltd.
• ASC Therapeutics